EGFR T790M阳性肺癌奥希替尼获得性耐药机制评估及临床意义
该研究纳入多机构队列143例和验证队列110例T790M阳性NSCLC患者,对奥希替尼耐药后活检行二代测序及血浆cfDNA基因分型。结果显示32%患者保留T790M并出现EGFR C797S,68%患者T790M丢失并涉及KRAS突变、可靶向基因融合等竞争性耐药机制,T790M丢失者治疗至停药时间更短。
要点
- 奥希替尼耐药后T790M丢失者治疗至停药时间更短(6.1 vs 15.2个月)。
- T790M丢失者存在KRAS突变、可靶向基因融合等多种竞争性耐药机制。
- T790M保留者中EGFR C797S是常见耐药机制(9/41,22%)。
核心结论
- 奥希替尼获得性耐药中T790M丢失介导的耐药与早期耐药及多种竞争性耐药机制相关。
- 晚期NSCLC耐药存在异质性,需要能克服多重耐药机制或预防耐药的临床试验策略。
研究设计与样本
- 多机构队列纳入143例接受奥希替尼治疗的T790M阳性晚期NSCLC患者,其中41例耐药后肿瘤活检行二代测序。
- 验证队列为NCT01802632试验中110例耐药后行血浆cfDNA基因分型的患者。
- 研究分析于2017年11月9日完成。
主要发现
- 41例耐药后测序患者中,13例(32%)保留T790M,其中9例(22%)检出EGFR C797S。
- 28例(68%)T790M丢失,检出包括获得性KRAS突变和可靶向基因融合在内的多种竞争性耐药机制。
- T790M丢失者治疗至停药时间短于T790M保留者(6.1 vs 15.2个月),并在110例血浆cfDNA验证队列中确认。
- 连续血浆突变EGFR检测显示,T790M丢失者治疗1至3周后EGFR驱动突变水平下降幅度更小(100% vs 83%,P = .01)。
临床怎么用
- 奥希替尼耐药后应行肿瘤活检二代测序及血浆cfDNA基因分型以明确耐药机制。
- T790M丢失提示早期耐药及多重竞争性耐药机制,需考虑相应临床试验策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M mutation. Acquired resistance to osimertinib is a growing clinical challenge that is poorly understood. OBJECTIVE: To understand the molecular mechanisms of acquired resistance to osimertinib and their clinical behavior. DESIGN, SETTING, AND PARTICIPANTS: Patients with advanced NSCLC who received osimertinib for T790M-positive acquired resistance to prior EGFR tyrosine kinase inhibitor were identified from a multi-institutional cohort (n = 143) and a confirmatory trial cohort (NCT01802632) (n = 110). Next-generation sequencing of tumor biopsies after osimertinib resistance was performed. Genotyping of plasma cell-free DNA was studied as an orthogonal approach, including serial plasma samples when available. The study and analysis were finalized on November 9, 2017. MAIN OUTCOMES AND MEASURES: Mechanisms of resistance and their association with time to treatment discontinuation on osimertinib. RESULTS: Of the 143 patients evaluated, 41 (28 [68%] women) had tumor next-generation sequencing after acquired resistance to osimertinib. Among 13 patients (32%) with maintained T790M at the time of resistance, EGFR C797S was seen in 9 patients (22%). Among 28 individuals (68%) with loss of T790M, a range of competing resistance mechanisms was detected, including novel mechanisms such as acquired KRAS mutations and targetable gene fusions. Time to treatment discontinuation was shorter in patients with T790M loss (6.1 vs 15.2 months), suggesting emergence of pre-existing resistant clones; this finding was confirmed in a validation cohort of 110 patients with plasma cell-free DNA genotyping performed after osimertinib resistance. In studies of serial plasma levels of mutant EGFR, loss of T790M at resistance was associated with a smaller decrease in levels of the EGFR driver mutation after 1 to 3 weeks of therapy (100% vs 83% decrease; P = .01). CONCLUSIONS AND RELEVANCE: Acquired resistance to osimertinib mediated by loss of the T790M mutation is associated with early resistance and a range of competing resistance mechanisms. These data provide clinical evidence of the heterogeneity of resistance in advanced NSCLC and a need for clinical trial strategies that can overcome multiple concomitant resistance mechanisms or strategies for preventing such resistance.
引用
- Oxnard GR, Hu Y, Mileham KF, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018. PMID: 30073261. doi:10.1001/jamaoncol.2018.2969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。